CB1R upregulation has also been reported in cancers such as prostatic adenocarcinoma, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma [17,25], while CB1R downregulation was demonstrated in colorectal carcinoma compared to healthy organ tissue [26]. This evidence concerns the gene CNR1 and prostate adenocarcinoma.